Free Trial

Achieve Life Sciences Q4 2022 Earnings Report

Achieve Life Sciences logo
$3.17 -0.05 (-1.55%)
As of 02/21/2025 04:00 PM Eastern

Achieve Life Sciences EPS Results

Actual EPS
-$0.83
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.07
One Year Ago EPS
-$0.76

Achieve Life Sciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Achieve Life Sciences Announcement Details

Quarter
Q4 2022
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Achieve Life Sciences Earnings Headlines

Collect $7k per month from Tesla’s SECRET dividend
There's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a traditional dividend, there's a way to collect up to $7,013 per month from Tesla… starting as early as next month. This backdoor strategy is changing the game for smart investors. Want to see how it works?
Achieve Life Sciences (ACHV) Gets a Buy from Lake Street
See More Achieve Life Sciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Achieve Life Sciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Achieve Life Sciences and other key companies, straight to your email.

About Achieve Life Sciences

Achieve Life Sciences (NASDAQ:ACHV), a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

View Achieve Life Sciences Profile

More Earnings Resources from MarketBeat